94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Xuehong Deng1,2,3,4,5†
Xiaoyan Xing1,2,3,4,5†
Guibo Sun1,2,3,4,5*
Xudong Xu1
Haifeng Wu1
Guang Li1,2,3,4,5,6
Xiaobo Sun1,2,3,4,5*- 1Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- 2Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, China
- 3Key Laboratory of Efficacy Evaluation of Chinese Medicine against Glycerolipid Metabolism Disorder Disease, State Administration of Traditional Chinese Medicine, Beijing, China
- 4Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, China
- 5Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China
- 6Yunnan Branch, Institute of Medicinal Plant, Chinese Academy of Medical Sciences and Peking Union Medical College, Jinghong, China
by Deng X, Xing X, Sun G, Xu X, Wu H, Li G and Sun X (2017). Front. Pharmacol. 8:777. doi: 10.3389/fphar.2017.00777
In the published article, there was an error in Figure 4 as published. In Figure 4A, the “Sham” and “High dose” group inadvertently used the same representative images as those in Figure 3A. The corrected Figure 4 appears below.
Figure 4
Figure 4. Echocardiogram parameters in MIRI-LVR rats treated with high-dose of GXDSF treated group and PHTPP. The echocardiograms (A) were obtained using the Vevo 770 high-resolution imaging system. LVEF and LVFS (B) data are also shown in bar graphs. Compared with the sham group, ###P < 0.001. Compared with the MIRI-LVR model group: *P < 0.01. Compared with the high-dose of GXDSF treated group: &P < 0.05, &&P < 0.01. The data are presented as the mean ± SD (n = 10 in each group).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Guanxin Danshen formula, myocardial ischemia reperfusion injury, ventricular remodeling, network pharmacology, estrogen receptor β, PI3K/Akt
Citation: Deng X, Xing X, Sun G, Xu X, Wu H, Li G and Sun X (2024) Corrigendum: Guanxin Danshen formulation protects against myocardial ischemia reperfusion injury-induced left ventricular remodeling by upregulating estrogen receptor β. Front. Pharmacol. 15:1488968. doi: 10.3389/fphar.2024.1488968
Received: 31 August 2024; Accepted: 23 September 2024;
Published: 08 October 2024.
Edited and reviewed by:
Michael Heinrich, University College London, United KingdomCopyright © 2024 Deng, Xing, Sun, Xu, Wu, Li and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Guibo Sun, c3VuZ3VpYm9AMTI2LmNvbQ==; Xiaobo Sun, c3VuX3hpYW9ibzE2M0AxNjMuY29t
†These authors have contributed equally to this work